Abstract 1878P
Background
The growing number of patients with genitourinary cancers (GU) could create an increasing burden on GU oncologists. Bureau for Cancer Research (BUCARE) describes the prevalence of burnout in GU oncologists in Central Asia region.
Methods
This is a cross-sectional survey study conducted among practicing cancer care physicians (surgical, medical, radiation) at the ASCO / Asian American GU Symposium ( Almaty, April 2023 ). The primary outcome was burnout experience assessed through the Maslach Burnout Inventory.
Results
A total of 101 oncologists completed the questionnaire. Table summarizes physician's characteristics. Despite the fact that 100% of responders are interested in their work, 66% (67 of 101) had symptoms of burnout (high emotional exhaustion and/or depersonalization scores). Fifty percent of oncologists are ready to turn to a psychologist for help. Significant drivers of burnout identified in multivariable regression modeling included ³20 patients per day (odds ratio [OR] = 14.8; P<0.001) and ³10 working hours per day (OR=8.6; P<0.001). Male gender (OR=0.14; P<0.001) and specialization in radiation therapy (OR=0.20; P<0.01) were associated with lower odds of burnout.
Conclusions
More than half of participants met predefined standardized criteria for burnout. Expanding the staff of GU oncologists and reducing the daily workload may improve the emotional state of physicians. Table: 1878P
Characteristics | N=101 |
Gender, N (%) | |
Female | 68 (67.3) |
Male | 33 (37.7) |
Region, N (%) | |
Kazakhstan | 85 (84.2) |
Other countries | 17 (16.8) |
Specialty, N (%) | |
Surgery | 39 (38.6) |
Medical Oncology | 44 (43.6) |
Radiation Oncology | 18 (17.8) |
Department, N (%) | |
In-patient | 79 (78.2) |
Out-patient | 22 (21.8) |
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2018P - Novel nomogram based on the expression of DLL3 and PD-L1 for predicting the prognosis of small cell lung cancer patients
Presenter: Jun Zhao
Session: Poster session 05
2019P - Analysis of lung immune prognostic index (LIPI) score in a small cell lung cancer carcinoma (SCLC) cohort, supporting its prognostic use and investigating its predictive potential
Presenter: Mónica Esteban García
Session: Poster session 05
2020P - Circulating micro RNAs (cmiRNAs) as treatment outcome predictors in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab plus carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2021P - Cell-free (cf) DNA as predictive biomarker (B) of treatment outcome in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab, carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2022P - ALBA project: Prognostic impact of laterality in small cell lung cancer
Presenter: Lorenza Landi
Session: Poster session 05
2024P - Supportive measures to control myelosuppression and costs for patients with SCLC with lurbinectedin, CAV or topotecan with or without trilaciclib: A review on the basis of clinical trials
Presenter: Manuel Dómine
Session: Poster session 05
2025P - Stratified control study of neuroendocrine differentiation and potential clinicopathologic markers
Presenter: Li Liu
Session: Poster session 05
2026P - Small cell lung cancer (SCLC) in the KBP-2020-CPHG cohort and comparison with 2000 and 2010
Presenter: Lionel Falchero
Session: Poster session 05
2027P - Immune checkpoint inhibitors in the treatment of small cell lung cancer: A systematic review and meta-analysis
Presenter: Patsy Lee
Session: Poster session 05